St. Jude Clinical Trials
CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms
Diseases Treated:
Eligibility:
- 1–22 years old
- Treatment-related or secondary MDS/AML
DIRECT70: CAR T–Cell Therapy for Children with Blood Malignancies
CAR T–Cell Therapy Directed to CD70 for Pediatric Patients with Hematological Malignancies (DIRECT70)
Diseases Treated:
Eligibility:
- Up to 21 years old
- CD70+ acute myeloid leukemia, acute lymphoblastic leukemia (B-ALL, T-ALL), lymphoma, or myelodysplastic syndrome
- If prior allogeneic hematopoietic cell transplant, no graft vs. host disease
- Has an identified hematopoietic cell transplantation donor
- Has adequate organ function
HAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia
Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosis of severe aplastic anemia
- No available matched donor
INSIGHT-HD: Investigating the Genetics of Hematologic Diseases
Diseases Treated:
Non-malignant blood diseases (non-therapeutic)
Eligibility:
- Receiving therapy or a consultation for a non-malignant blood disorder
- Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
LEAPS: Understanding Sickle Cell Disease Transition to Adult Care
Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition
Diseases Treated:
Eligibility:
This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.
- Diagnosis of sickle cell disease (SCD)
- 16 to 20 years old
- English is primary language
LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants
A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells
Diseases Treated:
X-linked Severe Combined Immunodeficiency (SCID-X1)
Eligibility:
- Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
- Newborn to 2 years of age
- No prior therapy with allogeneic stem cell transplantation
- No HIV infection
Collaborative Clinical Trials
BHEEM: Study of BEAM-101 in Patients with Severe Sickle Cell Disease
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 18 to 35 years old
- Diagnosed with severe sickle cell disease